Recently, studies have correlated tumour response and poor disease-free survival with loss of MLH1 expression in breast cancer tumours following anthracycline-based neoadjuvant chemotherapy (Mackay et al, 2000). The gene discussed is MLH1; the disease is breast carcinoma.